ERBB2 and neoplasm: A prolongation of PFS and OS in recurrent EOC was demonstrated in several clinical trials investigating the efficacy of NY-ESO-1-based vaccines,105,106 dendritic cell (DC) vaccines based on a pool of peptides (Her2/neu, hTERT, and PADRE peptides),107 or whole-tumor vaccines of autologous tumor cells infected with Newcastle disease virus,108 or viral oncolysate vaccine generated from EOC cell lines infected with influenza-A virus.109